TY - JOUR
T1 - The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma
AU - Chang, Cunjie
AU - Rajasekaran, Muthukumar
AU - Qiao, Yiting
AU - Dong, Heng
AU - Wang, Yu
AU - Xia, Hongping
AU - Deivasigamani, Amudha
AU - Wu, Minjie
AU - Sekar, Karthik
AU - Gao, Hengjun
AU - Sun, Mengqing
AU - Niu, Yuqin
AU - Li, Qian
AU - Tao, Lin
AU - Yan, Zhen
AU - Wang, Menglan
AU - Chen, Shasha
AU - Zhao, Shujuan
AU - Chen, Dajing
AU - Li, Lina
AU - Yang, Fan
AU - Gao, Haojin
AU - Chen, Baodong
AU - Su, Ling
AU - Xu, Liang
AU - Chen, Ye
AU - Seshachalam, Veerabrahma Pratap
AU - Chen, Gongxing
AU - Gunaratne, Jayantha
AU - Hong, Wanjin
AU - Shi, Junping
AU - Chen, Gongying
AU - Grierson, David S.
AU - Chabot, Benoit
AU - Xie, Tian
AU - Hui, Kam Man
AU - Chen, Jianxiang
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Deregulation of alternative splicing is implicated as a relevant source of molecular heterogeneity in cancer. However, the targets and intrinsic mechanisms of splicing in hepatocarcinogenesis are largely unknown. Here, we report a functional impact of a Splicing Regulatory Glutamine/Lysine-Rich Protein 1 (SREK1) variant and its regulator, Serine/arginine-rich splicing factor 10 (SRSF10). HCC patients with poor prognosis express higher levels of exon 10-inclusive SREK1 (SREK1L). SREK1L can sustain BLOC1S5-TXNDC5 (B-T) expression, a targeted gene of nonsense-mediated mRNA decay through inhibiting exon-exon junction complex binding with B-T to exert its oncogenic role. B-T plays its competing endogenous RNA role by inhibiting miR-30c-5p and miR-30e-5p, and further promoting the expression of downstream oncogenic targets SRSF10 and TXNDC5. Interestingly, SRSF10 can act as a splicing regulator for SREK1L to promote hepatocarcinogenesis via the formation of a SRSF10-associated complex. In summary, we demonstrate a SRSF10/SREK1L/B-T signalling loop to accelerate the hepatocarcinogenesis.
AB - Deregulation of alternative splicing is implicated as a relevant source of molecular heterogeneity in cancer. However, the targets and intrinsic mechanisms of splicing in hepatocarcinogenesis are largely unknown. Here, we report a functional impact of a Splicing Regulatory Glutamine/Lysine-Rich Protein 1 (SREK1) variant and its regulator, Serine/arginine-rich splicing factor 10 (SRSF10). HCC patients with poor prognosis express higher levels of exon 10-inclusive SREK1 (SREK1L). SREK1L can sustain BLOC1S5-TXNDC5 (B-T) expression, a targeted gene of nonsense-mediated mRNA decay through inhibiting exon-exon junction complex binding with B-T to exert its oncogenic role. B-T plays its competing endogenous RNA role by inhibiting miR-30c-5p and miR-30e-5p, and further promoting the expression of downstream oncogenic targets SRSF10 and TXNDC5. Interestingly, SRSF10 can act as a splicing regulator for SREK1L to promote hepatocarcinogenesis via the formation of a SRSF10-associated complex. In summary, we demonstrate a SRSF10/SREK1L/B-T signalling loop to accelerate the hepatocarcinogenesis.
UR - https://www.scopus.com/pages/publications/85126661719
U2 - 10.1038/s41467-022-29016-x
DO - 10.1038/s41467-022-29016-x
M3 - 文章
C2 - 35296659
AN - SCOPUS:85126661719
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 1363
ER -